Dr Bidwell wrote to Dr Maycock to ask if the Factor IX pool sizes could be increased to the maximum capacity of the freeze drier (360 bottles). Read more about Dr Bidwell wrote to Dr Maycock to ask if the Factor IX pool sizes could be increased to the maximum capacity of the freeze drier (360 bottles).
Dr Rainsford thought it was worth continuing to transfuse high potency factor IX because of its effectiveness and because no cases of hepatitis encountered were close to moderately severe. Read more about Dr Rainsford thought it was worth continuing to transfuse high potency factor IX because of its effectiveness and because no cases of hepatitis encountered were close to moderately severe.
Dr Maycock explained that Factor IX pools were sometimes created from 2 or 3 subpools increasing the pool size. Read more about Dr Maycock explained that Factor IX pools were sometimes created from 2 or 3 subpools increasing the pool size.
Batch history for BPL Factor IX concentrates indicates that Factor IX pool sizes were larger than those used to manufacture Factor VIII. Read more about Batch history for BPL Factor IX concentrates indicates that Factor IX pool sizes were larger than those used to manufacture Factor VIII.
A study conducted at Oxford shows 7 out of 16 Haemophilia B patients on regular treatment with Factor 9 concentrate who were tested for their liver function had a persistently abnormal Aspartate Aminotransferase ("AST") level. Read more about A study conducted at Oxford shows 7 out of 16 Haemophilia B patients on regular treatment with Factor 9 concentrate who were tested for their liver function had a persistently abnormal Aspartate Aminotransferase ("AST") level.
A study was being conducted "To study the incidence and types of factor VIII and IX related hepatitis in the U.K. by requesting the Directors of Haemophilia Centres to report cases as soon as they occur to the Oxford Haemophilia Centre". Read more about A study was being conducted "To study the incidence and types of factor VIII and IX related hepatitis in the U.K. by requesting the Directors of Haemophilia Centres to report cases as soon as they occur to the Oxford Haemophilia Centre".
In a Haemophilia and Blood Transfusion Working Group, Dr Cash expressed his concern about the inadequate tracing of patients and the lack of data available about Factor 9 usage. Read more about In a Haemophilia and Blood Transfusion Working Group, Dr Cash expressed his concern about the inadequate tracing of patients and the lack of data available about Factor 9 usage.
In a Haemophilia and Blood Transfusion Working Group, members discussed the setting up of clinical studies of Supernine which would lead to the issue of a product licence. Read more about In a Haemophilia and Blood Transfusion Working Group, members discussed the setting up of clinical studies of Supernine which would lead to the issue of a product licence.
In a report prepared for the Scottish Health Service Haemophilia Centre/Transfusion Service Directors' meeting, Dr Craske reported that Supernine was at an advanced stage of development. Read more about In a report prepared for the Scottish Health Service Haemophilia Centre/Transfusion Service Directors' meeting, Dr Craske reported that Supernine was at an advanced stage of development.
In a report prepared for the Scottish Health Service Haemophilia Centre/Transfusion Service Directors' meeting, Dr Craske described Haemophilia B patients as "a high risk group for hepatitis". Read more about In a report prepared for the Scottish Health Service Haemophilia Centre/Transfusion Service Directors' meeting, Dr Craske described Haemophilia B patients as "a high risk group for hepatitis".